Dietary Salicylates and Preeclampsia
Recruiting · NCT06239363 · Observational (researchers observe without assigning treatment) · Lead sponsor: Poznan University of Life Sciences
View the official record on ClinicalTrials.gov →What this trial is about
Preeclampsia (PE) is an important pregnancy complication and cause of maternal and perinatal mortality and morbidity. The underlying etiology and pathophysiology of preeclampsia is incompletely understood but it involves dysfunctional cytotrophoblastic invasion, placental ischemia, and release of inflammatory and endothelial mediators. Placenta dysfunction in PE is related to angiogenic balance. Currently, therapeutic options for the prevention and treatment of PE are limited. It is known that the risk of PE is reduced by low-dose aspirin. Therefore, the influence of salicylates on the development of PE seems to need to be investigated. This project plans to examine the preventive effects of food sources of salicylic acid and compare their effects with aspirin. Therefore, the aim of the present study is thus answer the following questions. whether the maternal dietary intake of salicylates is related to placental angiogenesis; 2. whether naturally occurring salicylates have the same effects on preeclampsia development and placental angiogenesis as aspirin. To answer these questions we plan to carry out a human study with pregnant women. Due to the above the planned research aims to determine the association between maternal dietary intake of salicylates and placental angiogenesis and the risk of preeclampsia development. Although PE remains an incurable disease, the results of this project will enable the development of dietary recommendations for the prevention and treatment of preeclampsia. Moreover, the results of this study may be useful in lowering the cost of maternal and fetal complications from preeclampsia and the cost of their hospitalization.
Who can take part
Inclusion criteria
- age 18-45 years
- healthy women with no previous adverse medical history and women with diagnosed preeclampsia
- singleton pregnancy
- people who have the full ability to give informed consent.
Exclusion criteria
- pregnancies with detectable fetal defects, chromosomal abnormalities, genetic syndromes
- infections
- history of chronic hypertension, metabolic disorder before or during pregnancy, or the presence of high-risk factors such as heart diseases, diabetes, and renal diseases.
Where it is running
1 location listed.
- Poznan University of Life Sciences - Poznan, Poland